Capstone Investment Advisors
CRNX icon

Capstone Investment Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Capstone Investment Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327K Buy
+9,012
New +$403K ﹤0.01% 1333
2025
Q4 		– Sell
-6,678
Closed -$278K – 1679
2025
Q3 		$278K Buy
+6,678
New +$214K ﹤0.01% 1681

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Capstone Investment Advisors's CRNX Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2026: 9,012 shares worth $327K. The stake represents ﹤0.01% of the portfolio and ranks #1333 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in CRNX as recently as Q3 2025.

Capstone Investment Advisors first reported a position in CRNX in Q3 2025 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Capstone Investment Advisors held 9,012 shares of Crinetics Pharmaceuticals worth $327K as of Q1 2026.
  • Crinetics Pharmaceuticals was a new Capstone Investment Advisors position in Q1 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1333 holding.
  • Capstone Investment Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.